MedPath

zinc supplementation; Ulcerative colitis

Phase 3
Recruiting
Conditions
ulcerative colitis disease.
Ulcerative colitis, unspecified
K51.9
Registration Number
IRCT20190712044182N3
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Body mass index between 18.5 and 35
?Diagnosis of ulcerative colitis according to the patient's symptoms, tests and colonoscopy, and intestinal sample pathology
Mild to moderate active form of the disease according to the Mayo questionnaire
Absence of concomitant diseases
not taking supplements containing zinc during the last 2 months
No use of infliximab, Sinora, high dose of corticosteroids (above 40 mg), NSAIDs
Not pregnant or lactating
Not taking contraceptives

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of clinical symptoms. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: Mayo questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath